Loading...
•
Sep 30, 2023
Mink Therapeutics Q3 2023 Earnings Report
Reported financial results for the third quarter 2023, with advancements in iNKT cell platform and progress in engineered programs.
Key Takeaways
MiNK Therapeutics reported its Q3 2023 financial results, highlighting advancements in its iNKT cell platform, progress in engineered programs, and strides in internal cGMP manufacturing. The company ended the quarter with a cash balance of $6.4 million. AgenT-797 has demonstrated promising results in patients with late-stage metastatic cancer.
AgenT-797 shows promising results in patients with late-stage metastatic cancer, with over 30% experiencing disease stabilization or biomarker responses.
A patient with gastric cancer achieved a durable clinical response with agenT-797.
A randomized phase 2 clinical trial of agenT-797 +/- standard of care chemotherapy +/- Agenus’ botensilimab/balstilimab in patients with 2L gastric cancer is on track to launch this year.
Ended the third quarter with a cash balance of $6.4 million.
Forward Guidance
MiNK Therapeutics is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...